Top

Clinical Drug Investigation

Published in:

01-06-2000 | Pharmacokinetics

Nateglinide, a New Mealtime Glucose Regulator

Lack of Pharmacokinetic Interaction with Digoxin in Healthy Volunteers

Authors: Honghui Zhou, Yulia H. Walter, Harold Smith, Damayanthi Devineni, Dr James F. McLeod

Published in: Clinical Drug Investigation | Issue 6/2000

Abstract

Objective: To investigate any possible pharmacokinetic interactions that may occur following the coadministration of nateglinide, a new mealtime glucose regulator, and digoxin.

Design and Setting: This was a partially randomised, three-period, nonblind, crossover study performed at a single centre in healthy male and female volunteers aged 19 to 36 years.

Methods: During treatment period 1, all study participants received nateglinide 120mg three times daily for 1 day. They were then randomised to two treatment sequences (n = 6 in each group) in periods 2 and 3, during which they received either a single dose of digoxin 1mg or the combination of nateglinide 120mg three times daily for 2 days plus a single dose of digoxin 1mg on the first day. Blood samples were collected and pharmacokinetic parameters derived. Safety variables measured included ECG parameters and blood pressure.

Results: The concurrent administration of nateglinide and digoxin did not affect the pharmacokinetics of either drug. On the basis of cardiac and haemodynamic assessments, there was no evidence of pharmacodynamic interaction between digoxin and nateglinide. During the study, nateglinide was well tolerated and there were no serious adverse events or drug-related discontinuations in volunteers receiving nateglinide alone or in combination with digoxin.

Conclusion: No adjustment of the dosage of either digoxin or nateglinide is necessary when the drugs are coadministered.

Aronow WS, Ahn C. Incidence of heart failure in 2,737 older persons with and without diabetes mellitus. Chest 1999; 115(3): 867–8PubMedCrossRef

Reuring RH, Geraets DR. Digoxin. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics. 2nd ed. Washington: Applied Therapeutics, 1986: 570–623

Miura T, Ueno K, Tanaka K, et al. Impairment of absorption of digoxin by acarbose. J Clin Pharmacol 1998; 38(7): 654–7PubMed

Ben-Ami H, Krivoy N, Nagachandran P, et al. An interaction between digoxin and acarbose. Diabetes Care 1999; 22(5): 860–1PubMedCrossRef

Serrano JS, Jimenez CM, Serrano MI, et al. A possible interaction of potential clinical interest between digoxin and acarbose. Clin Pharmacol Ther 1996; 60(5): 589–92PubMedCrossRef

Boyd RA, Stern RH, Stewart BH, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein—mediated secretion. J Clin Pharmacol 2000; 40(1): 91–8PubMedCrossRef

Verschraagen M, Koks CHW, Schellens JHM, et al. P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol Res 1999; 40(4): 301–6PubMedCrossRef

Fromm MF, Kim RB, Stein CM, et al. Inhibition of P-glycoprotein—mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999; 99(4): 552–7PubMedCrossRef

Shinkai H, Toi K, Kumashiro I, et al. N-Acylphenylalanines and related compounds. A new class of oral hypoglycemic agents. J Med Chem 1988; 31: 2092–7PubMedCrossRef

10.

Karara AH, Dunning BE, McLeod JF. The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects. J Clin Pharmacol 1999; 39: 172–9PubMedCrossRef

11.

Hirschberg Y, Karara AH, Pietri AO, et al. Improved control of mealtime glucose excursion with coadministration of nateglinide and metformin. Diabetes Care 2000; 23: 349–53PubMedCrossRef

12.

Keilson L, Mather S, Walter YH, et al. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000; 85: 1081–6PubMedCrossRef

13.

Hu S, Wang S. Effect of antidiabetic agent, nateglinide, on K_ATP channel in β-cells: comparison to glyburide and repaglinide [abstract]. Diabetologia 1998; 41 Suppl. 1: A139

14.

Cohen A, Kroon R, Seamaker R, et al. The bioavailability of digoxin from three oral formulations measured by specific HPLC assay. Br J Clin Pharmacol 1993; 35: 136–42PubMedCrossRef

Title: Nateglinide, a New Mealtime Glucose Regulator
Lack of Pharmacokinetic Interaction with Digoxin in Healthy Volunteers
Authors: Honghui Zhou
Yulia H. Walter
Harold Smith
Damayanthi Devineni
Dr James F. McLeod
Publication date: 01-06-2000
Publisher: Springer International Publishing
Published in: Clinical Drug Investigation / Issue 6/2000
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI: https://doi.org/10.2165/00044011-200019060-00009

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Nateglinide, a New Mealtime Glucose Regulator

Lack of Pharmacokinetic Interaction with Digoxin in Healthy Volunteers

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2000

Clinical Effectiveness of Irbesartan and Irbersartan plus Hydrochlorothiazide in Women with Mild to Moderate Essential Hypertension

Pharmacokinetics of Reboxetine in Volunteers with Hepatic Impairment

Antihyperlipidaemic Drugs

Butenafine 1% versus Terbinafine 1% in Cream for the Treatment of Tinea Pedis

Collagenase Ointment Application at 24-versus 48-hour Intervals in the Treatment of Pressure Ulcers

Influence of Drugs on Sleep Apnoea in Stroke Patients